Literature DB >> 9763525

Impaired insulin-stimulated glucose oxidation and free fatty acid suppression in patients with familial combined hyperlipidemia: a precursor defect for dyslipidemia?

L Karjalainen1, J Pihlajamäki, P Karhapää, M Laakso.   

Abstract

Familial combined hyperlipidemia (FCHL) is characterized by hyperlipidemia and insulin resistance, but intracellular defect in insulin action is unknown. Therefore, we investigated insulin action by applying the hyperinsulinemic euglycemic clamp technique with indirect calorimetry in 58 FCHL family members (28 with FCHL; 30 without dyslipidemia; aged 49+/-12 years; body mass index [BMI], 25. 2+/-4.0 kg/m2) and in 72 healthy control subjects (aged 54+/-6 years; BMI, 26.3+/-3.1 kg/m2). In the fasting state, FCHL patients had higher levels of total cholesterol, total triglycerides, and apolipoprotein B than control subjects (P<0.001 after adjustment for gender, age, and BMI). During the euglycemic clamp, FCHL patients had lower rates of glucose oxidation (15.93+/-3.55 versus 19.65+/-4. 60 micromol/kg/min; P=0.001) and higher rates of lipid oxidation (0. 15+/-0.13 versus 0.01+/-0.25 mg/kg/min; P=0.024), as well as higher levels of serum-free fatty acids (FFA) (0.24+/-0.17 versus 0.06+/-0. 06 mmol/L; P<0.001) compared with those of control subjects. Relatives without dyslipidemia differed similarly from control subjects with respect to rates of glucose and lipid oxidation and FFA suppression during the hyperinsulinemic clamp. In FCHL family members, during the euglycemic clamp FFAs correlated negatively with the rates of glucose oxidation (P<0.001) but not with the rates of glucose nonoxidation (P=0.408). In FCHL family members without dyslipidemia and in control subjects, FFAs during the clamp correlated positively with levels of total triglycerides (P<0.001) and very low density lipoprotein cholesterol (P=0.008). We conclude that in patients with FCHL, and also in their first-degree relatives, insulin's suppressive effect on FFA levels is impaired, which may precede dyslipidemia in FCHL.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9763525     DOI: 10.1161/01.atv.18.10.1548

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  4 in total

Review 1.  Metabolic pathogenesis of familial combined hyperlipidaemia with emphasis on insulin resistance, adipose tissue metabolism and free fatty acids.

Authors:  Jacqueline de Graaf; Mario J Veerkamp; Anton F H Stalenhoef
Journal:  J R Soc Med       Date:  2002       Impact factor: 5.344

2.  Distinct Dose-Dependent Association of Free Fatty Acids with Diabetes Development in Nonalcoholic Fatty Liver Disease Patients.

Authors:  Fuxi Li; Junzhao Ye; Yanhong Sun; Yansong Lin; Tingfeng Wu; Congxiang Shao; Qianqian Ma; Xianhua Liao; Shiting Feng; Bihui Zhong
Journal:  Diabetes Metab J       Date:  2021-03-15       Impact factor: 5.376

3.  Vitamin D concentrations in familial combined hyperlipidemia: effects of lipid lowering treatment.

Authors:  Inka Miñambres; Jose Luis Sánchez-Quesada; Joan Sánchez-Hernández; Jose Rodríguez; Alberto de Leiva; Antonio Pérez
Journal:  Diabetol Metab Syndr       Date:  2014-01-22       Impact factor: 3.320

4.  Free fatty acids profile among lean, overweight and obese non-alcoholic fatty liver disease patients: a case - control study.

Authors:  Rennan Feng; Chao Luo; Chunlong Li; Shanshan Du; Akinkunmi Paul Okekunle; Yanchuan Li; Yang Chen; Tianqi Zi; Yucun Niu
Journal:  Lipids Health Dis       Date:  2017-09-04       Impact factor: 3.876

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.